A study tracking eye scrapes in people with DEB
Part of Brain & nervous system, Eyes & vision, Genetic & congenital, Injuries & trauma, Skin clinical trials.
This study follows people with dystrophic epidermolysis bullosa (DEB) who get scrapes on the surface of their eye (corneal abrasions). It collects information to better understand how often and how severely these eye injuries happen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your legal guardian must agree to be in the study and follow all instructions.
- You must be at least 6 months old.
- You must have previously been diagnosed with dystrophic epidermolysis bullosa (DEB) through a genetic test that found a problem in a specific gene (COL7A1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the medical features and needs of people who have recessive dystrophic epidermolysis bullosa (RDEB). It may help doctors better understand the condition and plan better care.
This study looks at the immune system in people with recessive dystrophic epidermolysis bullosa (RDEB) and tests how placental stem cells affect immune cells in the lab. It aims to understand the disease better and explore potential treatments.
This trial tests a new skin graft made with your own cells that have been genetically modified to produce a missing protein (collagen 7). It's for people with RDEB, a severe blistering condition, and aims to see if the graft can heal wounds safely.
This study tests an experimental eye drop (KB803) to see if it can reduce painful scrapes on the surface of the eye in people with dystrophic epidermolysis bullosa. You would be randomly assigned to receive either the study drops or a placebo (an inactive drop) for several months.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
This study follows patients who have already received a gene therapy treatment called prademagene zamikeracel for a severe skin condition called recessive dystrophic epidermolysis bullosa (RDEB). The goal is to track long-term safety and health outcomes after treatment.
Hear when a new Epidermolysis Bullosa Dystrophica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.